The $700M Startup That's Never Sold a Drug Just Filed to Go Public

The company runs what it calls an integrated "drug hunting engine," combining small molecules (pills you swallow) with protein therapeutics (biologics that target things outside cells). They layer in AI and machine learning tools, backed by 25 to 30 data scientists, to speed up the notoriously slow process of finding and refining drug candidates.

Their pipeline includes four programs in discovery and four in preclinical or Phase 2 stages. The lead candidates target specific nodes in inflammatory signaling pathways: RIPK2, IRAK4, IRF5, and SLC15A4. Think of these as different switches in the immune system's control panel; Odyssey wants to flip each one off without shutting down the whole system.

A partnership with Terray Therapeutics supports their IRF5 inhibitor program, which goes after cytokine production in immune cells. None of these drugs are approved yet. None generate meaningful revenue. That's the bet investors are making.

Timing Is Everything

Odyssey's return to public markets isn't random. The 2026 biotech IPO window has blown wide open.

After a brutal 2025 that saw only about 11 biotech IPOs total, 2026 has already delivered a parade of massive listings. Kailera Therapeutics raised $625 million in April. Generate:Biomedicines pulled in roughly $400 million in February. Eikon Therapeutics grabbed $381 million in February. Aktis Oncology upsized from a $181 million target to $365 million in January.

Analysts project 30 to 35 biotech IPOs for the full year, the strongest class since 2021 when more than 100 biotechs priced IPOs. The common thread: investors want clinical-stage assets with near-term data catalysts.

The Platform Company Dilemma

But there's a catch, and it's one Odyssey should worry about.

Platform companies (those selling a discovery approach rather than a single product) have had a rougher ride post-IPO than product-focused peers. Both Generate:Biomedicines and Eikon Therapeutics priced their offerings successfully but traded below their IPO prices afterward. As PitchBook analyst Ben Zercher noted, "Product-focused companies built around clinically grounded programs are forming the backbone of the window, while larger platform-oriented issuers are testing how far investor appetite can extend beyond near-term validation."

Odyssey sits in an uncomfortable middle ground. It has eight pipeline programs, which signals breadth. But breadth without late-stage clinical proof can look like a science project rather than a pharmaceutical company. The $238.3 million raise suggests Odyssey believes it can thread this needle: enough programs advancing to convince investors that validation is coming, enough capital already raised to signal that serious money already believes.

The $700 Million Question

Let's zoom out. Odyssey has raised approximately $700 million in private capital since 2021. Its last private valuation (from the Series C extension in August 2024) was around $619 million. The Series D in September 2025 valued it at about $530 million.

With 151 employees, a full research platform, and multiple candidates moving toward the clinic, Odyssey has the infrastructure of a real drug company. Whether it becomes one depends on whether any of those eight programs actually work in patients.

For now, investors will decide if the combination of Glick's track record, a stacked team, $700 million in prior conviction, and a hot IPO window adds up to something worth $238.3 million more. Based on what the market has been buying in 2026, the answer might be yes.

But as every biotech investor knows: pedigree gets you to the podium. Only data keeps you there.